FDI World Dental Federation calls for global leaders to prioritise action against oral diseases at major UN meeting on health / Call issued on World Oral Health Day, as data shows oral diseases impact nearly half the world's population
mehr
Meldungen zum Thema Krankheit
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
REVEAL GENOMICS®´ BREAKTHROUGH TECHNOLOGY ENTERS THE LIQUID BIOPSY FIELD IN ONCOLOGY
Barcelona, Spain (ots/PRNewswire) - - REVEAL GENOMICS®´ machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors. - This new approach provides multi-feature genomic predictors from ctDNA for breast cancer and other types of ...
mehrMedison Pharma; Alnylam Pharmaceuticals
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
Zug, Switzerland (ots/PRNewswire) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their ...
mehrServier Announces Partnership with QIAGEN to Develop New mIDH1 Companion Diagnostic Test to Support Servier's Onco-hematology Portfolio
Paris (ots/PRNewswire) - Servier, a global pharmaceutical group, today announced it has entered into a strategic partnership with QIAGEN, a leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life, to develop ...
mehrDEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Lausanne, Switzerland (ots) - Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, today announced having ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Brain scans of people with MS help us understand the effects of Covid
Bern (ots) - People affected by multiple sclerosis need to undergo regular MRI brain scans. The images are now being used to visualise the effects of a coronavirus infection. Brain fog, memory problems, loss of the sense of smell - Covid-19 affects the brain in a number of ways, yet the mechanisms behind this remain largely unknown. This is because disease-related changes in our brains are almost impossible to detect if ...
mehr
Servier receives a positive CHMP opinion for Tibsovo® in IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma (CCA) patients
Paris (ots/PRNewswire) - - Tibsovo® (ivosidenib tablets) is the first IDH1 inhibitor recommended for approval in Europe - The positive CHMP opinion is based on clinical data from the AGILE (in AML) and ClarIDHy (in CCA) studies Servier, a global pharmaceutical company, today announced that the Committee for ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
A quiet crisis manager
mehrHuma, Camden Health Partners and UCLPartners launch digital-first population health programme to identify and manage cardiovascular disease
London (ots/PRNewswire) - - Aim is to prevent avoidable heart attacks and strokes in North London - Expands primary care capacity by utilising digital tools to identify and manage high risk individuals - Advances proactive, predictive care for people at risk of the world's leading cause of death1 Huma Therapeutics ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Avoiding burnout of white blood cells
mehrSchweizerische Multiple Sklerose Gesellschaft
2Swiss Multiple Sclerosis Society awards first MS research prize
mehrPlumCare RWE partners with Lifebit on Greece's newborn genomic sequencing program, BeginNGS
London (ots/PRNewswire) - - PlumCare RWE and Lifebit enter a three-year partnership to support Greece's pioneering national newborn genomic sequencing program, BeginNGS. - Researchers will be able to access and analyse data securely in combination with global cohorts, whilst ensuring data is kept safe, private and in place in their secure environment using Lifebit's ...
mehr
Schweizerischer Nationalfonds / Fonds national suisse
Novel approaches to health care
mehrEagle Genomics' Scale-Up Funding from OMRON Ventures to Drive Sustainability Innovation in Microbiome R&D
Cambridge, England (ots/PRNewswire) - - OMRON Ventures joins existing investors abrdn, Environmental Technologies Fund and consortium led by Granpool Innovative Investments - Scale-up focused on enabling novel, sustainable scientific innovations that harness the microbiome to solve for 'One Health' challenges, ...
mehrLargest decentralised study of its kind shows high levels of engagement with Huma's study app
London (ots/PRNewswire) - - More than 90% of 2,524 participants invited to join a fully virtual COVID-19 study, run by Cambridge researchers, downloaded and registered on the study app1 - Around 75% of participants completed digital biomarker assessments such as resting heart rate, temperature and oxygen saturation at least once per week1 - Participants were aged 45 - ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots/PRNewswire) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a ...
mehrDEBIOPHARM APPLIES EXTENDED-RELEASE FORMULATION EXPERTISE TO REDUCE TREATMENT FREQUENCY BURDEN FOR ACROMEGALY & GEP-NET PATIENTS
Lausanne, Switzerland (ots) - - Acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare diseases that require life-long chronic treatment. Monthly somatostatin analog (SSA) injections are the standard of care as first-line medical treatment. - Debiopharm is developing Debio 4126, a novel ...
mehrMars Petcare and the Broad Institute create open-access database of dog and cat genomes to advance preventive pet care
New York (ots/PRNewswire) - - The genome database will power ongoing scientific efforts worldwide and help advance individualized pet health care - Insights from this partnership will feed into the MARS PETCARE BIOBANK™, a longitudinal study to understand pet health and disease, transforming pet care for future ...
mehr
Huma to provide best-in-class digital clinical trials solutions through landmark acquisition of Alcedis
London and Frankfurt, Germany (ots/PRNewswire) - - Acquisition combines award-winning digital health platform with global clinical research expertise acquired over 25 years - Creates new and advanced digital solutions across all phases of clinical trials - Accelerates patient recruitment and the development of new ...
mehrCirculating Tumor Cell detection by Menarini Group's CELLSEARCH® System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Huntingdon Valley, Pa. (ots/PRNewswire) - Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems' CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with ...
mehrHearing loss company Acousia Therapeutics completes clinical Phase 1 study with its small molecule
Tübingen, Germany (ots) - Hearing loss company Acousia Therapeutics GmbH announced the successful completion of its ACOU085 clinical Phase 1b study today, following the final visit of the last patient treated with the highest ACOU085 dose. ACOU085 is a proprietary small-molecule drug candidate under clinical ...
mehrLUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference ...
mehrEagle Genomics Announces USD 20M First Close; Scale-up Funding to Accelerate the Application of Microbiome Science for Global 'One Health' Innovation
Cambridge, England (ots/PRNewswire) - - Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion - Platform business focused on bridging the current 'translation gap', addressing critical bottlenecks in the ...
mehrSchweizerischer Nationalfonds / Fonds national suisse
Improving the efficacy of antibiotics and curbing resistance
Bern (ots) - New findings from NRP 72, financed by the Swiss National Science Foundation, are helping to curb antibiotic resistance. In the field of new antibiotics, however, structures needed for translating results into practice are lacking. Worldwide, more and more pathogens are becoming resistant to today's antibiotics. As antibiotics lose their efficacy, infections that were once easy to treat can give rise to fatal ...
mehr
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
London (ots/PRNewswire) - Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa - Early customers include GP offices and other community-based healthcare settings - Latest figures, released as part of World Diabetes Day, reveal that 1 in 10 adults are now living with diabetes and nearly ...
mehrTauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
mehrTauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability - Shareholder ...
mehrMedison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
Petach Tikvah, Israel (ots/PRNewswire) - With this latest expansion, Medison's global footprint is now extended across Israel, Central and Eastern Europe, Canada, Asia-Pacific and Latin America, offering patients in international markets improved access to highly innovative therapies. Medison Pharma ("Medison"), a global pharma company focused on providing access to ...
mehrTES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis
Perugia, Italy (ots/PRNewswire) - INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and ...
mehrForging a healthier future through research: McGill University launches new Institute of Genomic Medicine
Montreal (ots/PRNewswire) - Landmark donation from alumnus Dr. Victor Phillip Dahdaleh will accelerate advances in global health using genomic medicine to inform patient diagnosis and care A landmark donation to support McGill University's renowned genomics research and education programs from UK-based alumnus and ...
mehr
Vorherige12345678910Nächste